Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01693692 | Phase 2 Study of TD-9855 to Treat Fibromyalgia | PHASE2 | COMPLETED | 392 | — | — | Nov 1, 2012 | Apr 1, 2014 | Mar 4, 2022 | 34 | United States |
Pain NRS score is based on an 11-point scale where 0 represents no pain and 10 represents the worst possible pain.
| Arm | Type | Description |
|---|---|---|
| TD-9855 Group 1 | EXPERIMENTAL | Group 1 to be dosed with TD-9855 |
| TD-9855 Group 2 | EXPERIMENTAL | Group 2 to be dosed with TD-9855 |
| Placebo | PLACEBO_COMPARATOR | Group to be dosed with Placebo |
| Name | Type | Description |
|---|---|---|
| TD-9855 Group 1 | DRUG | - |
| TD-9855 Group 2 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * • American College of Rheumatology (ACR) Diagnostic Criteria for Fibromyalgia (FM) * Informed consent * 18 to 65 years of age * Discontinue therapy with adrenergic-acting drugs, and certain other medications * Only acetaminophen or NSAID as rescue pain medication ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Axsome Therapeutics, Inc. | AXSM | 1 | PHASE3 | AXS-14 |
| Grace Therapeutics, Inc. | GRCE | 1 | — | Undisclosed |